Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 68

Sort by

Sort Order Select

Journal Articles

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Ioannis Ntanasis-Stathopoulos, Eirini Katodrytou, Evdoxia Hatjiharissi, Emmanouil Spanoudakis, Vasiliki Douka, Despina Fotiou, Vasiliki Labropoulou, Dimitra Dalampira, Vasiliki Spiliopoulou, Theodosia Papadopoulou, Dimitrios Christoulas, Panagiotis Malandrakis, Anthi Bouchla, Vasiliki Pappa, Efstathios Kastritis, Evangelos Terpos, Meletios Dimopoulos, Maria Gavriatopoulou

Blood (2024) 144 (Supplement 1): 6988.

https://doi.org/10.1182/blood-2024-206900

Published: 2024

Journal Articles

Distinct T Cell Receptor Gene Repertoires and T Cell Subset Distribution in Peripheral Blood and Bone Marrow of Patients with Multiple Myeloma

Glykeria Gkoliou, Nikolaos Pechlivanis, Sofia Chatzileontiadou, Chara Xydopoulou, Christina Frouzaki, Georgios Karakatsoulis, Elisavet Vlachonikola, Marina Gerousi, Fotis Psomopoulos, Maria Papaioannou, Katerina Chlichlia, Kostas Stamatopoulos, Evdoxia Hatjiharissi, Anastasia Chatzidimitriou

Blood (2023) 142 (Supplement 1): 4677.

https://doi.org/10.1182/blood-2023-185872

Published: 2023

Journal Articles

Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients

Sophia Adamia, Daisuke Ogiya, Evdoxia Hatjiharissi, Michael P. Chu, Zuzana Chyra, Kenneth Wen, Yu-Tzu Tai, David M. Dorfman, Teru Hideshima, Kenneth C. Anderson

Blood (2022) 140 (Supplement 1): 2081–2082.

https://doi.org/10.1182/blood-2022-169943

Published: 2022

Journal Articles

T Cell Epitope Prediction within the Clonotypic Immunoglobulin Heavy and Light Chains in Patients with Multiple Myeloma

Glykeria Gkoliou, Nikos Pechlivanis, Sofia Chatzileontiadou, Chara Xydopoulou, Christina Frouzaki, Georgios Karakatsoulis, Elisavet Vlachonikola, Marina Gerousi, Fotis Psomopoulos, Maria Papaioannou, Katerina Chlichlia, Kostas Stamatopoulos, Evdoxia Hatjiharissi, Anastasia Chatzidimitriou

Blood (2022) 140 (Supplement 1): 12444–12445.

https://doi.org/10.1182/blood-2022-159992

Published: 2022

Journal Articles

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Efstathios Kastritis, Evangelos Terpos, Argiris Symeonidis, Sosana Delimpasi, Michele Cavo, Elena Zamagni, Eirini Katodritou, Elena Rivolti, Marie-Christine Kyrtsonis, Maria Roussou, Despina Fotiou, Evdoxia Hatjiharissi, Nikolaos Kanellias, Magdalini Migkou, Alexandros Leonidakis, Kyriaki Manousou, Maria Gavriatopoulou, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2729.

https://doi.org/10.1182/blood-2021-153075

Published: 2021

Journal Articles

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Evangelos Terpos, Maria Gavriatopoulou, Eirini Katodritou, Evdoxia Hatjiharissi, Ioanna Dialoupi, Evgenia Verrou, Alexandros Leonidakis, Magdalini Migkou, Sosana Delimpasi, Argiris Symeonidis, Efstathios Kastritis, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 2737.

https://doi.org/10.1182/blood-2021-153082

Published: 2021

Journal Articles

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Evangelos Terpos, Efstathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, Evangelos Eleutherakis Papaiakovou, Evgenia Verrou, Maria Gavriatopoulou, Alexandros Leonidakis, Ioannis Ntanasis-Stathopoulos, Sosana Delimpasi, Marie-Christine Kyrtsonis, Maria Papaioannou, Argiris Symeonidis, Meletios A. Dimopoulos

Blood (2021) 138 (Supplement 1): 1672.

https://doi.org/10.1182/blood-2021-152385

Published: 2021

Journal Articles

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

Evangelos Terpos, MDPhD, Efstathios Kastritis, MD, Evdoxia Hatjiharissi, MD, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD, Maria Papaioannou, MD, Argiris Symeonidis, MD PhD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-140261

Published: 2020

Journal Articles

T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study

Elisavet Vlachonikola, PhD, Efstathios Kastritis, MD, Evdoxia Hatjiharissi, MD, Eirini Katodritou, MD, Alexandra Siorenta, MD, Electra Sofou, Marina Gerousi, Konstantia Kotta, Maria Karipidou, Maria Gavriatopoulou, Sosana Delimpasi, MD, Argiris Symeonidis, MD PhD, Kostas Stamatopoulos, MD, Meletios A Dimopoulos, Evangelos Terpos, MDPhD, Anastasia Chatzidimitriou

Blood (2020) 136 (Supplement 1): 28.

https://doi.org/10.1182/blood-2020-139236

Published: 2020

Journal Articles

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Efstathios Kastritis, MD, Evangelos Terpos, MDPhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, Eirini Katodritou, MD, Elena Rivolti, MD, Marie-Christine Kyrtsonis, MD, Maria Gavriatopoulou, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, MD, Nikolaos Kanellias, MD, Magdalini Migkou, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 48–49.

https://doi.org/10.1182/blood-2020-140322

Published: 2020

Journal Articles

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

Evangelos Terpos, MDPhD, Maria Gavriatopoulou, Eirini Katodritou, MD, Evdoxia Hatjiharissi, MD, Ioanna Dialoupi, MD, Evgenia Verrou, MD, Alexandros Leonidakis, PhD, Magdalini Migkou, Sosana Delimpasi, MD, Argiris Symeonidis, MD PhD, Efstathios Kastritis, MD, Meletios A Dimopoulos

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-140301

Published: 2020

Journal Articles

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Blood (2020) 136 (Supplement 1): 33–35.

https://doi.org/10.1182/blood-2020-138390

Published: 2020

Journal Articles

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Evangelos Terpos, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Evangelos Eleutherakis-Papaiakovou, MD, Evgenia Verrou, MD, Maria Gavriatopoulou, MD, Alexandros Leonidakis, PhD, Ioannis Ntanasis-Stathopoulos, MD, Sosana Delimpasi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Papaioannou, Argiris Symeonidis, MD PhD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1837.

https://doi.org/10.1182/blood-2019-124638

Published: 2019

Journal Articles

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

Alexia Katsarou, Nikolaos Trasanidis, Jaime Alvarez-Benayas, Foteini Papaleonidopoulou, Keren Keren, Ioannis V. Kostopoulos, Kanagaraju Ponnusamy, Xiaolin Xiao, Niklas Feldhahn, Irene Roberts, Evdoxia Hatjiharissi, Maria Papaioannou, Ian Sudbery, Aristeidis Chaidos, Valentina S Caputo, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 3783.

https://doi.org/10.1182/blood-2019-122371

Published: 2019

Journal Articles

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Eftathios Kastritis, Evangelos Terpos, MD PhD, Argiris Symeonidis, MD PhD, Sosana Delimpasi, MD, Michele Cavo, Elena Zamagni, MD, Eirini Katodritou, MD, Barbara Gamberi, MD, Marie-Christine Kyrtsonis, MD PhD, Maria Gavriatopoulou, MD, Maria Roussou, MD, Despina Fotiou, MD, Evdoxia Hatjiharissi, Nikolaos Kanellias, MD, Magdalini Migkou, MD, Meletios A. Dimopoulos, MD

Blood (2019) 134 (Supplement_1): 1881.

https://doi.org/10.1182/blood-2019-124630

Published: 2019

Journal Articles

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Nikolaos Trasanidis, Jaime Alvarez-Benayas, Alexia Katsarou, Aristeidis Chaidos, Philippa C May, Kanagaraju Ponnusamy, Xiaolin Xiao, Marco Bua, MD, Maria Atta, MD, Irene Roberts, Holger W Auner, MD PhD, Evdoxia Hatjiharissi, Maria Papaioannou, Valentina S Caputo, Ian Sudbery, Anastasios Karadimitris

Blood (2019) 134 (Supplement_1): 1769.

https://doi.org/10.1182/blood-2019-124761

Published: 2019

Journal Articles

Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study)

Elisavet Vlachonikola, Anna Vardi, MD PhD, Eftathios Kastritis, Evdoxia Hatjiharissi, Eirini Katodritou, MD, Alexandra Siorenta, MD, Electra Sofou, Konstantia Kotta, Maria Karipidou, Maria Gavriatopoulou, MD, Sosana Delimpasi, MD, Argiris Symeonidis, MD PhD, Kostas Stamatopoulos, Meletios A. Dimopoulos, MD, Evangelos Terpos, MD PhD, Anastasia Chatzidimitriou

Blood (2019) 134 (Supplement_1): 3167.

https://doi.org/10.1182/blood-2019-124655

Published: 2019

Journal Articles

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Blood (2018) 132 (Supplement 1): 1978.

https://doi.org/10.1182/blood-2018-99-115725

Published: 2018

Journal Articles

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Blood (2016) 128 (22): 2954.

https://doi.org/10.1182/blood.V128.22.2954.2954

Published: 2016

Journal Articles

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Blood (2016) 128 (22): 5476.

https://doi.org/10.1182/blood.V128.22.5476.5476

Published: 2016

NARROW

Real-World Outcomes of Patients with Relapsed/Refractory Multiple Myeloma Treated with Teclistamab and Talquetamab; A Multicenter Analysis from the Greek Myeloma Study Group

Distinct T Cell Receptor Gene Repertoires and T Cell Subset Distribution in Peripheral Blood and Bone Marrow of Patients with Multiple Myeloma

Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients

T Cell Epitope Prediction within the Clonotypic Immunoglobulin Heavy and Light Chains in Patients with Multiple Myeloma

Efficacy and Safety of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment or on Dialysis: Final Analysis of the Phase 2 Dare Study

Safety and Efficacy of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Outcomes of the Phase 2 Daria Study

Impact of Daratumumab Monotherapy on Bone Metabolism Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least Two Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor: Outcomes of the Phase 2 Rebuild Study

Efficacy of Daratumumab Monotherapy on Bone Metabolism of Patients with Advanced Relapsed/Refractory Multiple Myeloma: Results from the Phase 2 Rebuild Study

T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study

Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: Results on Efficacy and Safety of the Phase 2 Dare Study

Efficacy and Tolerability of Daratumumab with Ixazomib and Dexamethasone in Patients with One Prior Lenalidomide-Based Regimen: Preliminary Results of the Phase 2 Daria Study

Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study

Impact of Daratumumab Monotherapy on Bone Parameters in Patients with Relapsed and/or Refractory Multiple Myeloma Who Have Received at Least 2 Prior Lines of Therapy Including Lenalidomide and a Proteasome Inhibitor; Interim Analysis of a Phase 2 Study (the REBUILD Study)

Oncogenic MAF in Co-Operation with IRF4 Confers Extensive Chromatin Re-Arrangement in Plasma Cells and Generates 'Neo-Enhancers' That Regulate Genes Critical for Myeloma Biology

Efficacy of Daratumumab with Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma and Severe Renal Impairment: An Interim Analysis of a Phase 2 Study (the DARE Study)

Distinct Chromatin Accessibility Changes, Aberrant Transcription Factor Networks Combined with Novel Oncogenic Enhancers Characterise Myeloma-Initiating Genetic Events

Longitudinal T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: A Subanalysis of a Phase 2 Study (the REBUILD Study)

Second Primary Malignancies and Disease Transformation in Newly Diagnosed Symptomatic Patients with Waldenstrom's Macroglobulinemia: An Analysis from the Greek Myeloma Study Group

Survivorship in WM: Identification of Factors Associated with Survival of More Than a Decade and with Early WM-Related Death

Ruxolitinib Remains Effective in Myelofibrosis after the Necessary Dose Reductions: Real-Life Data from a Multi-Center Observational Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only